A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers
about
Antidepressants for smoking cessationInterventions for preventing weight gain after smoking cessationAntidepressants for smoking cessationAntidepressants for smoking cessationMAO-inhibitors in Parkinson's DiseaseBacoside A: Role in Cigarette Smoking Induced Changes in BrainTargeting the noradrenergic system for gender-sensitive medication development for tobacco dependenceNew Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?Constitutional mechanisms of vulnerability and resilience to nicotine dependenceChronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs.Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.Nicotinic Receptors: Role in Addiction and Other Disorders of the Brain.A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers.Hypothesis for temporal displacement of metabolic and neuronal accommodation in smoking addiction.Brain monoamine oxidase A inhibition in cigarette smokers.Advances in pharmacotherapy for tobacco dependence.Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence.Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition.Effect of nonnicotine pharmacotherapy on smoking behavior.The potential of dopamine agonists in drug addiction.Genetic influences on smoking: candidate genes.Targeting nicotine addiction: the possibility of a therapeutic vaccine.Selegiline transdermal system (STS) as an aid for smoking cessation.Current and emerging pharmacotherapies for treating tobacco dependence.Monoamine oxidase inhibition for tobacco pharmacotherapy.Economic evaluation of pharmaco- and behavioral therapies for smoking cessation: a critical and systematic review of empirical research.Contribution of Monoamine Oxidase Inhibition to Tobacco Dependence: A Review of the Evidence.Nicotine: abused substance and therapeutic agent.A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch.Relationships between effects of smoking, gender, and alcohol dependence on platelet monoamine oxidase-B: activity, affinity labeling, and protein measurements.Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation.Why are antidepressant drugs effective smoking cessation aids?The separate and combined effects of monoamine oxidase inhibition and nicotine on P50 sensory gating.Platelet monoamine oxidase (MAO) activity and alcoholism: is there a genuine association?
P2860
Q24201167-05693998-2082-4347-8B45-22D926D004D6Q24203883-51655FCF-35BF-471F-AE56-34455398AF69Q24245969-83653514-D407-47A3-8A06-51623033080EQ24246426-D5AD0EF3-736D-49D5-9933-2D22BB509C9FQ24629770-42264DE6-E726-44B4-8407-E5059BF9625CQ26786019-F3AE0FE8-E10D-4D92-8595-C0C5F84A1F0CQ26999258-2B2CF934-F491-4F17-87FE-7FC64E58B106Q28277165-544DD900-5C65-42B2-A946-B2F52AB6127BQ30365559-2E3E8181-2B40-41A8-AD89-58F4E5257F00Q33299388-CED3F095-7969-40EA-B6ED-AA0DAD78A47AQ33582051-A95E60BB-5C6E-457C-AADB-B873EFAFDF56Q33635666-818016EB-4AC9-47EC-9A62-3ECC90447FC4Q33653805-010FD6FF-A4A4-4950-BDAB-13A9CF592C2EQ33815480-A3F0FE68-8E64-4C42-AC2E-66805BCD692CQ34063791-D13C1CD6-CA11-4B0C-8020-8039AF3939E9Q34322083-3F702332-328B-487A-BB25-21111A08FF6DQ34366802-F7F9A433-64C4-4BB6-970E-5870EECFB34DQ34464750-4B315646-F708-4A7B-9755-BFD89D1268D0Q34476913-820BE321-2E6A-4112-9D7A-6EA835C8ECFFQ34581491-F446C5A1-4BA5-46E0-911D-57E0092BE1D2Q34938233-035D6EA6-E7BF-4847-8F1C-BF1C0DF4B271Q34987300-0CE93E17-50C4-4C85-9A2E-10D297A6E9A7Q35761733-E34FFF8F-A488-4A0E-BE76-DF21FAA42F11Q36580581-E0FF08D8-73E9-4C9E-8649-0CEE55D1C4A3Q36937130-A57E0D31-E66F-45CD-BEC0-0D68385BB8EFQ37648843-B481EF1C-84D8-407F-AC53-5014EB1F9789Q38617975-343F15D8-9CAD-4B18-9C4A-E04601E46FA7Q41741650-AD1589BE-9A0C-4C3C-A0CF-F569E80947ABQ42641590-7B0744E8-985E-4ECB-8075-A368981F2AE2Q44096219-2AE46255-D17E-4250-8B62-A493BC7E1BE1Q44163654-ABFD12B6-F89C-48C1-AC69-9E1AA6B58E97Q47765206-6C3C9EC9-B6AB-43E2-924C-C8550FC6E185Q50608280-1D9D9554-68DF-437E-9A62-B01E43AC472FQ52308403-2EA74A59-AB03-4EA2-A74F-C5ABDB9AEA02
P2860
A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers
description
1995 nî lūn-bûn
@nan
1995 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
name
A reversible monoamine oxidase ...... ce in heavy, dependent smokers
@ast
A reversible monoamine oxidase ...... ce in heavy, dependent smokers
@en
A reversible monoamine oxidase ...... ce in heavy, dependent smokers
@nl
type
label
A reversible monoamine oxidase ...... ce in heavy, dependent smokers
@ast
A reversible monoamine oxidase ...... ce in heavy, dependent smokers
@en
A reversible monoamine oxidase ...... ce in heavy, dependent smokers
@nl
prefLabel
A reversible monoamine oxidase ...... ce in heavy, dependent smokers
@ast
A reversible monoamine oxidase ...... ce in heavy, dependent smokers
@en
A reversible monoamine oxidase ...... ce in heavy, dependent smokers
@nl
P2093
P2860
P1476
A reversible monoamine oxidase ...... ce in heavy, dependent smokers
@en
P2093
J M Launay
O Spreux-Varoquaux
R Olivares
Y Lecrubier
P2860
P304
P356
10.1016/0009-9236(95)90058-6
P407
P577
1995-10-01T00:00:00Z